ViGeneron – pharmaceutical daily

April 6, 2022 Off

ViGeneron Signs Gene Therapy Strategic Collaboration and Option Agreement with Regeneron for One Inherited Retinal Disease Target

By Author

ViGeneron GmbH, a next-generation gene therapy company, has announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).

November 28, 2019 Off

ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China

By Dino Mustafić

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.